Following the discontinuation of its EX1 drug delivery platform, Arrowhead Pharmaceuticals has come back with its Targeted RNAi Molecule (TRiM™) technology and signed a two-part deal with Janssen Pharmaceuticals worth potentially US$3.75 B. The first part grants Janssen worldwide rights to its hepatitis B candidate, ARO-HBV, that showed promising early-stage results and the second part is an option to license agreement for up to three candidates against targets to be selected by Janssen utilising the TRiM™ platform. In addition, Johnson & Johnson Innovation made an equity investment in the company of US$75 M.